Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 0.63 |
| ▸ | SLC5A1 | P13866 | 12/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.60 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13016199 | 0.90 | SLC5A2 (0.64) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL13062802 | 0.89 | SLC5A2 (0.74) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL13062672 | 0.88 | SLC5A2 (0.75) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL1713525 | 0.86 | SLC5A2 (0.79) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL14260937 | 0.85 | SLC5A2 (0.61) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL13062803 | 0.85 | SLC5A2 (0.61) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL13016185 | 0.85 | SLC5A2 (0.63) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL13062671 | 0.84 | SLC5A2 (0.64) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL13062809 | 0.82 | SLC5A2 (0.77) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL154622 | 0.82 | SLC5A2 (0.70) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858587-B2 | Glucopyranosyl-substituted difluorobenzyl-benzene derivates, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-28 | — | — | US | disclosed |
| US-20100081625-A1 | METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | US | disclosed |
| US-20090318547-A1 | GLUCOPYRANOSYL-SUBSTITUTED DIFLUOROBENZYL-BENZENE DERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-24 | — | — | US | disclosed |
| WO-2008090210-A1 | METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-31 | — | — | WO | disclosed |
| WO-2008034859-A1 | GLUCOPYRANOSYL-SUBSTITUTED DIFLUOROBENZYL-BENZENE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081625-A1 | METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISORDERS | HTT, SNCA, PSEN2 | SLC5A2 59/4885SLC5A1 41/4885ADRA2A 2392/4885 |
| US-20090318547-A1 | GLUCOPYRANOSYL-SUBSTITUTED DIFLUOROBENZYL-BENZENE DERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | UGGT1, SLC5A2, SLC5A1 | SLC5A2 2/4885SLC5A1 3/4885ADRA2A 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.